SearchDictionaryMobileLogin

Oscar Cirioni Selected Research

Infection

07/2008BMAP-28 improves the efficacy of vancomycin in rat models of gram-positive cocci ureteral stent infection.
12/2007RNAIII-Inhibiting Peptide Affects Biofilm Formation in a Rat Model of Staphylococcal Ureteral Stent Infection.
11/2007Pretreatment with the protegrin IB-367 affects Gram-positive biofilm and enhances the therapeutic efficacy of linezolid in animal models of central venous catheter infection.
04/2007Distinctin improves the efficacies of glycopeptides and betalactams against staphylococcal biofilm in an experimental model of central venous catheter infection.
09/2006Pre-treatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection.
06/2006Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection.
01/2006RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated Staphylococcus aureus infections.
10/2005Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus.
09/2005In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients.
12/2004BisEDT and RIP act in synergy to prevent graft infections by resistant staphylococci.
08/2004Temporin A soaking in combination with intraperitoneal linezolid prevents vascular graft infection in a subcutaneous rat pouch model of infection with Staphylococcus epidermidis with intermediate resistance to glycopeptides.
07/2004A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci.
10/2003Prophylactic efficacy of linezolid alone or combined with levofloxacin and vancomycin in a rat subcutaneous pouch model of graft infection caused by Staphylococcus epidermidis with intermediate resistance to glycopeptides.
08/2003Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat Pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides.
11/2002Temporin A as a prophylactic agent against methicillin sodium-susceptible and methicillin sodium-resistant Staphylococcus epidermidis vascular graft infection.
09/2002Efficacy of quinupristin-dalfopristin in preventing vascular graft infection due to Staphylococcus epidermidis with intermediate resistance to glycopeptides.

Articles by Research Topic

Disease

16Infection
07/2008 - 09/2002
9Septic Shock (Toxic Shock Syndrome)
08/2006 - 01/2002
8Sepsis (Septicemia)
10/2008 - 07/2004
3Peritonitis
01/2008 - 11/2002
2Wounds and Injuries (Trauma)
06/2008 - 04/2008
2Staphylococcal Infections
06/2007 - 07/2004
1Wound Infection (Wound Infections)
01/2008
1Pseudomonas Infections
12/2007
1Obstructive Jaundice (Cholestatic Jaundice)
11/2006
1Endotoxemia
09/2006
1Surgical Wound Infection
11/2005
1Pneumonia (Pneumonitis)
03/2005

Drug/Important Bio-Agent (IBA)

7RNAIII inhibiting peptideIBA
06/2008 - 08/2003
6temporinIBA
04/2008 - 11/2002
5GlycopeptidesIBA
04/2007 - 09/2002
5PeptidesIBA
09/2006 - 01/2002
4BMAP-28IBA
07/2008 - 12/2004
4VancomycinFDA LinkGeneric
07/2008 - 10/2003
4PiperacillinFDA Link
01/2008 - 11/2003
4linezolid (Zyvox)FDA Link
11/2007 - 10/2003
4CAP18 lipopolysaccharide-binding protein (Bac4)IBA
09/2006 - 01/2004
4Anti-Bacterial Agents (Antibiotics)IBA
06/2006 - 02/2005
3tazobactamIBA
01/2008 - 12/2007
3pexigananIBA
09/2005 - 09/2004
2Granulocyte Colony-Stimulating Factor (G-CSF)IBA
10/2008 - 01/2008
2Tachypleus tridentatus tachyplesin peptideIBA
01/2008 - 12/2007
2antimicrobial peptide IB-367 (iseganan)IBA
11/2007 - 11/2003
2quinupristin-dalfopristin (Synercid)FDA Link
10/2005 - 09/2002
2Ofloxacin (Levofloxacin)FDA LinkGeneric
10/2003 - 01/2002
1TeicoplaninIBA
01/2008
1indolicidinIBA
01/2008
1Rifampin (Rifampicin)FDA LinkGeneric
07/2007
1Colistin (Coly-Mycin)FDA Link
07/2007
1lysyllysine (Lys-Lys)IBA
06/2007
1BMAP-27IBA
11/2006
1ertapenem (Invanz)FDA Link
08/2006
1tritrpticinIBA
08/2006
1ImipenemFDA Link
11/2005
1Anti-Infective Agents (Microbicides)IBA
11/2005
1Ciprofloxacin (Cipro)FDA LinkGeneric
10/2005
1Saralasin (Saralasin Acetate)FDA Link
03/2005
11,2-ethanedithiol (ethanedithiol)IBA
12/2004
1P-113DIBA
07/2004
1RNA (Ribonucleic Acid)IBA
07/2004
1dermaseptinIBA
07/2004
1Insecta cecropin B proteinIBA
02/2004
1Methicillin (Metin)FDA Link
11/2002
1MagaininsIBA
01/2002
1Polymyxin B (Aerosporin)FDA LinkGeneric
01/2002
1Polymyxins (Polymyxin)IBA
01/2002

Therapy/Procedure

8Transplants (Transplant)
06/2007 - 09/2002
3Stents
07/2008 - 12/2007